• LAST PRICE
    57.4600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    56.9400/ 13
  • Ask / Lots
    56.9900/ 15
  • Open / Previous Close
    --- / 57.4600
  • Day Range
    ---
  • 52 Week Range
    Low 42.6300
    High 58.9700
  • Volume
    26
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract
    • 1 hour ago by Dow Jones
      Companies Mentioned: SNY

      By Andrea Figueras

      Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare cancers using radiation.
    • 1 hour ago by Dow Jones
      Companies Mentioned: SNY

      complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
    • 2 hours ago by Dow Jones
      Companies Mentioned: SNY

      By Andrea Figueras

      Sanofi said it entered into an exclusive licensing agreement with U.S. clinical-stage biotechnology company RadioMedix and Orano Med, a French subsidiary of the Orano Group, to develop innovative treatments for rare cancers.
    • 3 hours ago by Dow Jones
      Companies Mentioned: SNY

      This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • Yesterday

      Show headlines and story abstract
    • 18 hours ago by Dow Jones
      Companies Mentioned: SNY

      09:51 ET -- Sanofi is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Sanofi said its dupixent drug met the primary and all key secondary endpoints in a study evaluating its use in adults with moderate-to-severe bullous pemphigoid, a chronic and relapsing disease characterized by intense itch and blisters, reddening of the skin and painful chronic lesions. The drug also met primary and key secondary endpoints in a phase 3 study for the treatment of patients with uncontrolled, biologic-naive chronic spontaneous urticaria, or CSU, receiving background therapy with antihistamines. CSU is a chronic skin condition that causes sudden and debilitating hives and persistent itch. Dow Jones & Co. owns Factiva. (zaeem.shoaib@wsj.com)

Peers Headlines